



Fig. S1. Immunohistochemical staining against the amino-terminal end of type I procollagen using SP1.D8 antibody (original magnification $\times 200$). The figures on the left are representative of biopsies taken from 6 subjects in each group. A graph on the right represents the change from baseline in type I procollagen expression at 24 weeks. No decrease in type I procollagen protein expression was observed in all vehicle-treated subjects.

Table SI. Human primer sequences for quantitative real-time PCR

	5' primer sequence	3' primer sequence
h36B4*	TCG ACA ATG GCA GCA TCT AC	TGA TGC AAC AGT TGG GTA GC
hFibrillin-1	GGT GAA TGT ACA AAC ACA GTC AGC A	ATA GGA ACA GAG CAC AGC TTG TTG A
hProcol α 1(I)	CCC CAG CCA CAA AGA GTC TA	CTG TAC GCA GGT GAT TGG TG
hMMP-1	AAG CGT GTG ACA GTA AGC TA	AAC CGG ACT TCA TCT CTG
hGreb1	CAA AGA ATA ACC TGT TGG CCC TGC	GAC ATG CCT GCG CTC TCA TAC TTA

*h36B4 was used as an endogenous control gene.

Table SII. Skin elasticity measured with Cutometer after treatment with 1% oestrone or vehicle cream in photoaged facial skin

Treatment duration	Vehicle (n=38) Mean ± SD	Oestrone 1% (n=38) Mean ± SD	p-value
Before treatment			
R2	0.6447 ± 0.0959	0.6315 ± 0.1465	0.646
R5	0.6107 ± 0.1896	0.6173 ± 0.2026	0.884
R7	0.3305 ± 0.0645	0.3280 ± 0.0881	0.888
12 weeks			
R2	0.6241 ± 0.0917	0.6263 ± 0.0932	0.915
R5	0.5788 ± 0.2019	0.5742 ± 0.1278	0.905
R7	0.3303 ± 0.0686	0.3245 ± 0.0553	0.768
24 weeks			
R2	0.6129 ± 0.0770	0.6119 ± 0.0718	0.952
R5	0.5705 ± 0.0935	0.5909 ± 0.1120	0.392
R7	0.3218 ± 0.0474	0.3264 ± 0.0529	0.691

SD: standard deviation.